Browsing Category
Featured Articles
NIH-funded researchers reverse congenital blindness in mice
Researchers funded by the National Eye Institute (NEI) have reversed congenital blindness in mice by changing supportive cells in the retina called Müller glia into rod photoreceptors.…
Read More...
Read More...
Janssen Reports Positive Topline Results for ATLAS Phase III Study of a Novel, Long Acting…
The Janssen Pharmaceutical Companies of Johnson & Johnson confirmed positive topline results from the global, Phase III Antiretroviral Therapy as Long-Acting Suppression (ATLAS)…
Read More...
Read More...
Almac Discovery, Elasmogen and Innovate UK Collaborate to Develop VNAR Based Oncology Platform
Almac Discovery, a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, and Elasmogen, an SME focused on the development…
Read More...
Read More...
Solid Tumors Targeted in New CAR T-Cell Immunotherapy Trial
Seattle Children’s has opened a chimeric antigen receptor (CAR) T-cell immunotherapy trial for children and young adults with relapsed or refractory non-central nervous system…
Read More...
Read More...
Ambys Medicines and Takeda Announce Partnership to Pioneer First-in-Class Therapies for the…
Ambys Medicines and Takeda Pharmaceutical Company Limited announced that they have entered into a partnership to support the advancement of the Ambys platform and pipeline.
“We are…
Read More...
Read More...
Amgen Breaks Ground On Next-Generation Biomanufacturing Plant In Rhode Island
Amgen announced the groundbreaking of its new next-generation biomanufacturing plant that will be constructed at its West Greenwich, R.I. campus. The new plant is the first-of-its-kind…
Read More...
Read More...
PRIME designation granted by EMA for RG6042 for treatment of Huntington’s disease
Roche announced that the European Medicines Agency (EMA) has granted PRIME (PRIority MEdicines) designation for the company’s investigational medicine RG6042 (formerly known as…
Read More...
Read More...
Novartis marks a new era for migraine patients with the EU approval of Aimovig
Novartis announced that the European Commission (EC) approved Aimovig (erenumab) for the prevention of migraine in adults experiencing four or more migraine days per month. Aimovig is…
Read More...
Read More...
Selumetinib granted orphan designation in Europe for neurofibromatosis type 1
AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US (known as MSD outside the US and Canada) announced that the European Medicines Agency (EMA) has granted orphan designation to…
Read More...
Read More...
LEO Pharma to Expand Its Lead in Medical Dermatology with Acquisition of Bayer’s Prescription…
LEO Pharma and Bayer announced that LEO Pharma has entered into a definitive agreement to buy Bayer’s global prescription dermatology unit. The portfolio to be acquired includes branded…
Read More...
Read More...
MilliporeSigma and InnoCore Pharmaceuticals to Improve Patient Compliance with New Drug Delivery…
MilliporeSigma and InnoCore Pharmaceuticals; Groningen, Netherlands, have entered into a global cooperation agreement to provide InnoCore’s proprietary SynBiosys biodegradable polymer…
Read More...
Read More...
KEYTRUDA (pembrolizumab) is the First Anti-PD-1 Therapy Approved in China for Advanced Melanoma
Merck, known as MSD outside the United States and Canada, announced that KEYTRUDA, Merck’s anti-PD-1 therapy, has been approved by the China National Drug Administration (CNDA) for the…
Read More...
Read More...
PureTech Health Announces Collaboration with Roche to Advance Technology for Oral Administration of…
PureTech Health plc announced that it has entered into a multiyear collaboration with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., to advance PureTech’s milk-derived exosome…
Read More...
Read More...
AbbVie Receives FDA Approval of ORILISSA for endometriosis pain
AbbVie in cooperation with Neurocrine Biosciences announced that the U.S. Food and Drug Administration (FDA) approved ORILISSA™ (elagolix), the first and only oral…
Read More...
Read More...
GSK and 23andMe sign agreement to leverage genetic insights for the development of novel medicines
GSK and 23andMe unveiled an exclusive four-year collaboration that will focus on research and development of innovative new medicines and potential cures, using human genetics as the…
Read More...
Read More...
PolyU – Axis Therapeutics Joint Center for Immunotherapy Launched to Develop Innovative Cancer…
The Hong Kong Polytechnic University (PolyU) will join forces with Axis Therapeutics, a newly established joint venture by two global biopharmaceutical companies - Athenex, Inc. and…
Read More...
Read More...
New ALS therapy in clinical trials
About 20,000 people in the United States are living with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. The invariably fatal disease kills the nerve cells that…
Read More...
Read More...
Janssen Announces FDA Approval of SYMTUZA STR for HIV-1
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved SYMTUZA, the first and only complete,…
Read More...
Read More...
Sanofi and Revolution Medicines partner to develop cancer treatments
Sanofi and REVOLUTION Medicines announced an exclusive worldwide partnership to develop and commercialize targeted therapies, based on the biology of the cellular enzyme SHP2, for…
Read More...
Read More...
FDA grants Breakthrough Therapy Designation for Roche’s Tecentriq
Roche announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) as…
Read More...
Read More...